UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Management of pregnant women with chronic liver disease: Key points of vigilance

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Management of pregnant women with chronic liver disease: Key points of vigilance

Nathalie Ganne-Carrié 1

Affiliations

1 Hôpital Jean Verdier, APHP et Université Paris 13, Paris, France

Summary

AI Generated

Pre-pregnancy counselling and multidisciplinary management are recommended for women with chronic liver disease, as cirrhosis is an independent risk factor for adverse perinatal outcomes and variceal bleeding is the main cause of decompensation during pregnancy.

The speaker stated that maternal mortality or liver transplantation occurs in less than 1% of pregnant women with cirrhosis, while decompensation is significantly higher in those with previous decompensation, with variceal bleeding occurring in up to 62% of women who decompensate.
The speaker reported that MELD score below 6 predicts excellent pregnancy outcome, while MELD score over 10 is predictive of decompensation, and low preconception ALBI and APRI scores predict live birth and pregnancy proceeding to term.
Screening endoscopy should be performed within one year prior to pregnancy to assess for clinically significant varices, or during early second trimester if not done before, as endoscopy is safe during pregnancy with left lateral positioning.
Beta blockers should be continued or initiated during pregnancy for variceal prophylaxis if no contraindication, high-risk varices should undergo endoscopic band ligation, and terlipressin is contraindicated as it can cause uterine contractions and decreased uterine blood flow.
Vaginal delivery is preferred with mode of delivery based on obstetrical determinants only, and most drugs used in chronic liver disease management are safe and should not be stopped as this could lead to clinical deterioration.
The speaker recommended that combined hormonal contraception should be avoided in women with history of intrahepatic cholestasis of pregnancy, pre-existing cholestatic liver disease, severe hepatitis, decompensated cirrhosis, or history of thrombosis without anticoagulation.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Hepatobiliary Paediatrics

Session

Liver and pregnancy: Beware of dangerous liaisons

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Smart choices in systemic HCC therapy

Anna Saborowski 1

Affiliations

1 Hannover Medical School, Hannover, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Digestive Oncology Hepatobiliary

Session

Hepatocellular carcinoma: All you need to know

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Management of advanced HCC

Melanie Bathon 1

Affiliations

1 Medizinische Hochschule Hannover, Hannover, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Digestive Oncology Hepatobiliary

Session

Hepatocellular carcinoma: All you need to know

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

The clinical spectrum of mesenteric ischemia

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz 1

Affiliations

1 Erasmus Medical Center Rotterdam, Rotterdam, Netherlands

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Radiology & Imaging Small Intestine & Nutrition

Session

Acute and chronic mesenteric ischaemia

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

When should I refer a patient with PSVD to a center of expertise?

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens 1

Affiliations

1 Ghent University Hospital, Gent, Belgium

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Hepatobiliary

Session

Metabolic and vascular disorders of the liver

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

Clinical care pathways in MASH

Kushala Abeysekera 1

Affiliations

1 Bristol Medical School, University of Bristol, London, United Kingdom

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Postgraduate Teaching Programme Berlin 2025

Topics

Hepatobiliary

Session

Metabolic and vascular disorders of the liver

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Bénédicte Caron 1, Elodie Jeanbert 1, Florian Poullenot 2, Yoram Bouhnik 3, Lucine Vuitton 4, Catherine Reenaers 5, Stephane NANCEY 6, pierre Blanc 7, Xavier Roblin 8, Stéphanie Viennot 9, Jean-Louis Dupas 10, Anne Laure Pelletier 11, Arnaud Bourreille 12, Jacques Moreau 13, Jerome Filippi 14, Maria Nachury 15, Guillaume Bouguen 16, Marion Simon 17, Ludovic Caillo 18, Anthony Buisson 19, Laurianne Plastaras 20, Vered Abitbol 21, Alexandre Aubourg 22, Médina Boualit 23, David Laharie 24, Laurent Peyrin-Biroulet 25

Affiliations

1 Nancy University Hospital, Vandoeuvre les Nancy, France

2 Bordeaux University Hospital, Bordeaux, France

3 CHU Beaujon Dept. of IBD and Nutrition, Clichy, France

4 Besançon university hospital gastroenterology, Courbevoie, France

5 Assistants en formation gastro, réseau Ulg - CHU Sart Tilman, Assistants en formation gastro, réseau, Lantremange, Belgium

6 Lyon University Hospital, Pierre Benite, France

7 Hopital Saint Eloi, Montpellier, France

8 University of St. Etienne Dept. de Gastroenterologie, Saint Etienne, France

9 CHRU de Caen HGE 19è étage, Caen Cedex, France

10 CHU Nord Amiens, Amiens, France

11 Hopital Beaujon, Paris, France

12 Hopital Hotel Dieu Et Hme - Hge Aile Sud, Nantes Cedex 1, France

13 Centre Hospitalier Universitaire de Toulouse, Hopital Rangueil, Toulouse, France

14 Hopital de lAchet Dept. de Gastroenterlogie Dept. de Nutrition Oncologie, Nice Cedex 3, France

15 CHRU Lille, Courbevoie Cedex, France

16 CHU Pontchaillou, Rennes, France

17 Institut Mutualiste Montsouris, Paris, France

18 CHU DE NIMES, Nîmes, France

19 CHU Estaing Clermont-Ferrand, Clermont-ferrand, France

20 Chu Colmar, Colmar, France

21 Hopital Cochin Gastroentérologie AP-HP, Paris Cedex 14, France

22 Cabinet Medical, Chambray Les Tours, France

23 Ch Valenciennes, Valenciennes Cedex, France

24 CHU de Bordeaux Hopital Haut-Leveque Dept. de Gastroenterologie, Pessac cedex, France

25 Inserm U1256, Nancy University Hospital, Vandoeuvre-les-Nancy, France

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Crohn's disease (CD) is a disabling and destructive disease. Early intervention associated with tight monitoring appear to the best way to achieve deep remission and to prevent disease progression. Whether anti-TNF (tumor necrosis factor) therapy can be interrupted in patients with early CD who have undergone a period of prolonged deep remission is unknown.

Aims & Methods

The primary objective was to evaluate the sustained deep remission rate one year after discontinuation of a 12-month course of adalimumab in adult patients with early CD who achieved deep remission at 12 months after treatment induction and who were already in clinical remission and biomarker remission at 6 months.
We carried out a multicentre prospective GETAID cohort study. All patients had early luminal CD less than 24 months since diagnosis, and were naïve to biologics. The primary study endpoint was percentage of patients with sustained deep remission one year after stopping a 12-months course of adalimumab (+/- 3 months) in adult patients with early-stage CD who achieved deep remission without therapeutic intervention (i.e. no surgery, no clinical flare-up, no introduction of CD-related treatment, no need for adalimumab optimization) AND who were already in clinical remission (CDAI < 150) and biomarker remission (CRP < 5 mg/L and fecal calprotectin < 250) at 6 months. A clinical flare-up was defined as a CDAI > 220 or an increase in CDAI between two subsequent visits > 70.

Results

A total of 171 patients received treatment with adalimumab between March 2015 and March 2019.
In this cohort, 39.2% (67/171) were active smokers. The median disease duration was 4 [2-9] months. CD location was ileal (42.7%, 73/171), colonic (12.3%, 21/171), and ileo colonic (44.4%, 76/171). Twenty-one patients (12.3%) had perianal disease. The majority of patients had an inflammatory phenotype (71.3%, 122/171). At inclusion, median CRP level was 9.0 [3.0-24.0] mg/L, and median fecal calprotectin was 440.5 [159.0-838.0] µg/g.
Overall, 38/171 (22.2%) of patients achieved deep remission after a 12-month course of adalimumab. From those who achieved deep remission, 7 patients did not discontinue adalimumab. In this study, 7/31 (22.6%) patients maintained their deep remission for one year after their treatment discontinuation (24 months from initiation of adalimumab). Among the whole cohort, only 4% (7/171) of patients were in deep remission off adalimumab at 2 years. Median time between adalimumab discontinuation and the first clinical relapse was 14 months. No predictive factor associated with loss of deep remission in the year following treatment discontinuation was identified. No serious adverse event was reported.

Conclusion

In this first prospective trial exploring withdrawal of advanced therapy in early CD, 22.6% achieved deep remission at one year with adalimumab; among them, about a quarter maintained deep remission at two years. These results demonstrate that anti-TNF therapy should not be discontinued, even in patients with early CD.

Event

UEG Week Berlin 2025

Topics

IBD Mechanisms & Personalised Medicine

Submission format

Abstract

Session

Clinical management of IBD

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

Smart choices in systemic HCC therapy

Anna Saborowski

Management of advanced HCC

Melanie Bathon

The clinical spectrum of mesenteric ischemia

Eva Karina Bocharewicz

When should I refer a patient with PSVD to a center of expertise?

Sarah Raevens

Clinical care pathways in MASH

Kushala Abeysekera

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Lucine Vuitton